L
Lennart Nilsson
Researcher at Lund University
Publications - 868
Citations - 39057
Lennart Nilsson is an academic researcher from Lund University. The author has contributed to research in topics: Molecular dynamics & Population. The author has an hindex of 82, co-authored 861 publications receiving 34898 citations. Previous affiliations of Lennart Nilsson include Royal Institute of Technology & Chalmers University of Technology.
Papers
More filters
Journal ArticleDOI
CHARMM: the biomolecular simulation program.
Bernard R. Brooks,Charles L. Brooks,Alexander D. MacKerell,Lennart Nilsson,Robert J. Petrella,Benoît Roux,Youngdo Won,Georgios Archontis,Christian Bartels,Stefan Boresch,Amedeo Caflisch,Leo S. D. Caves,Qiang Cui,Aaron R. Dinner,Michael Feig,Stefan Fischer,Jiali Gao,Milan Hodošček,Wonpil Im,K. Kuczera,Themis Lazaridis,Jianpeng Ma,V. Ovchinnikov,Emanuele Paci,Richard W. Pastor,Carol Beth Post,Jingzhi Pu,M. Schaefer,Bruce Tidor,Richard M. Venable,H. L. Woodcock,Xiongwu Wu,Wei Yang,Darrin M. York,Martin Karplus,Martin Karplus +35 more
TL;DR: An overview of the CHARMM program as it exists today is provided with an emphasis on developments since the publication of the original CHARMM article in 1983.
Journal ArticleDOI
Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K
Pekka Mark and,Lennart Nilsson +1 more
TL;DR: In this paper, the effects of velocity rescaling on the self-diffusion coefficient D and radial distribution functions, gOO, gOH, and gHH for all five water models were determined and compared to experimental data.
Journal ArticleDOI
Optimization of the CHARMM additive force field for DNA: Improved treatment of the BI/BII conformational equilibrium.
Katarina Hart,Nicolas Foloppe,Christopher M. Baker,Elizabeth J. Denning,Lennart Nilsson,Alexander D. MacKerell +5 more
TL;DR: The new CHARMM model better reproduces experimentally observed sampling of the BII conformation, including sampling as a function of sequence, and yields a stable Z-DNA conformation of duplex (GTACGTAC) in its crystal environment.
Journal ArticleDOI
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux,Aristoteles Giagounidis,Dominik Selleslag,Odile Beyne-Rauzy,Ghulam J. Mufti,Moshe Mittelman,Petra Muus,Peter A. W. te Boekhorst,Guillermo Sanz,Consuelo del Cañizo,Agnes Guerci-Bresler,Lennart Nilsson,Uwe Platzbecker,Michael Lübbert,Bruno Quesnel,Mario Cazzola,Arnold Ganser,David G. Bowen,Brigitte Schlegelberger,Carlo Aul,Robert Knight,John Francis,Tommy Fu,Eva Hellström-Lindberg +23 more
TL;DR: Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome and the safety profile was consistent with previous reports.